GFAP and glaucoma: The peptain-treated groups showed slightly lower numbers of activated microglia (Fig. 6A, B), and GFAP immunoreactivity (Fig. 6C, D), suggesting that peptains are capable of reducing neuroinflammation in SO-induced glaucoma.